Emerging Therapies in Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1 SUPPL., 2012, Pages

  Reddy, Pavan ^a   De Lima, Marcos ^b   Koreth, John ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Allogeneic; Azacytidine; Bortezomib; HDAC; Hypomethylating agent; Proteasome; Review

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BORTEZOMIB; CYCLOSPORIN; FLUDARABINE; GIVINOSTAT; METHOTREXATE; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY; VORINOSTAT;

ACUTE GRAFT VERSUS HOST DISEASE; ADOPTIVE IMMUNOTHERAPY; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; DOSE RESPONSE; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NEUROPATHY; NONHUMAN; RELAPSE; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; AZACITIDINE; BORONIC ACIDS; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYDROXAMIC ACIDS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 84855370552     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.022     Document Type: Article

References (59)

1. Flowers M.E., Inamoto Y., Carpenter P.A., et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011, 117:3214-3219.
2. Ho V.T., Soiffer R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001, 98:3192-3204.
3. Soiffer R.J., Lerademacher J., Ho V., et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011, 117:6963-6970.
4. Ho V.T., Kim H.T., Liney D., et al. HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant 2006, 37:845-850.
5. Hideshima T., Richardson P., Chauhan D., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61:3071-3076.
6. Ghosh S., May M.J., Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998, 16:225-260.
7. Wang X., Luo H., Chen H., Duguid W., Wu J. Role of proteasomes in T cell activation and proliferation. J Immunol 1998, 160:788-801.
8. Sunwoo J.B., Chen Z., Dong G., et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001, 7:1419-1428.
9. Finn P.W., Stone J.R., Boothby M.R., Perkins D.L. Inhibition of NF-kappaB-dependent T cell activation abrogates acute allograft rejection. J Immunol 2001, 167:5994-6001.
10. Nencioni A., Schwarzenberg K., Brauer K.M., et al. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 2006, 108:551-558.
11. Hirai M., Kadowaki N., Kitawaki T., et al. Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis. Blood 2011, 117:500-509.
12. Blanco B., Perez-Simon J.A., Sanchez-Abarca L.I., et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006, 107:3575-3583.
13. Sun K., Welniak L.A., Panoskaltsis-Mortari A., et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A 2004, 101:8120-8125.
14. Sun K., Wilkins D.E., Anver M.R., et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 2005, 106:3293-3299.
15. Vodanovic-Jankovic S., Hari P., Jacobs P., Komorowski R., Drobyski W.R. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood 2006, 107:827-834.
16. Sayers T.J., Brooks A.D., Koh C.Y., et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003, 102:303-310.
17. Hallett W.H., Ames E., Motarjemi M., et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. JImmunol 2008, 180:163-170.
18. Yong A.S., Keyvanfar K., Hensel N., et al. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by invitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 2009, 113:875-882.
19. Liu X., Yue P., Chen S., et al. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 2007, 67:4981-4988.
20. Schumacher L.Y., Vo D.D., Garban H.J., et al. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). JImmunol 2006, 176:4757-4765.
21. Lundqvist A., Abrams S.I., Schrump D.S., et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 2006, 66:7317-7325.
22. Rock K.L., Gramm C., Rothstein L., et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994, 78:761-771.
23. Spisek R., Charalambous A., Mazumder A., Vesole D.H., Jagannath S., Dhodapkar M.V. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007, 109:4839-4845.
24. Koreth J., Stevenson K.E., Kim H.T., et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 2009, 114:3956-3959.
25. Lee S.J. Have we made progress in the management of chronic graft-vs-host disease?. Best Pract Res Clin Haematol 2010, 23:529-535.
26. Kroger N., Zabelina T., Ayuk F., et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 2006, 34:770-775.
27. Sun K., Li M., Sayers T.J., Welniak L.A., Murphy W.J. Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation. Blood 2008, 112:1522-1529.
28. Lundqvist A., Yokoyama H., Smith A., Berg M., Childs R. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood 2009, 113:6120-6127.
29. Issa J.P., Garcia-Manero G., Giles F.J., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103:1635-1640.
30. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
31. de Lima M., Ravandi F., Shahjahan M., et al. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer 2003, 97:1242-1247.
32. Pinto A., Maio M., Attadia V., Zappacosta S., Cimino R. Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2'-deoxycytidine. Lancet 1984, 2:867-868.
33. Pinto A., Attadia V., Fusco A., Ferrara F., Spada O.A., Di Fiore P.P. 5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 1984, 64:922-929.
34. Hambach L., Ling K.W., Pool J., et al. Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy. Blood 2009, 113:2715-2722.
35. Jabbour E., Giralt S., Kantarjian H., et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009, 115:1899-1905.
36. Braun T.M., Thall P.F., Nguyen H., de Lima M. Simultaneously optimizing dose and schedule of a new cytotoxic agent. Clin Trials 2007, 4:113-124.
37. Andersson B.S., Valdez B.C., de Lima M., et al. Clofarabine +/- fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 2010, 17:893-900.
38. Platzbecker U., Wermke M., Radke J., et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2011.
39. Sanchez-Abarca L.I., Gutierrez-Cosio S., Santamaria C., et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood 2010, 115:107-121.
40. Choi J., Ritchey J., Prior J.L., et al. Invivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 2010, 116:129-139.
41. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
42. Allfrey V.G., Pogo B.G., Littau V.C., Gershey E.L., Mirsky A.E. Histone acetylation in insect chromosomes. Science 1968, 159:314-316.
43. Yang X.J., Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008, 9:206-218.
44. Mann B.S., Johnson J.R., Cohen M.H., Justice R., Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12:1247-1252.
45. Duvic M., Talpur R., Ni X., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109:31-39.
46. Leoni F., Zaliani A., Bertolini G., et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 2002, 99:2995-3000.
47. Leoni F., Fossati G., Lewis E.C., et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines invitro and systemic inflammation invivo. Mol Med 2005, 11:1-15.
48. Reddy P., Maeda Y., Hotary K., et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 2004, 101:3921-3926.
49. Reddy P., Sun Y., Toubai T., et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 2008, 118:2562-2573.
50. Mishra N., Reilly C.M., Brown D.R., Ruiz P., Gilkeson G.S. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 2003, 111:539-552.
51. Skov S., Rieneck K., Bovin L.F., et al. Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression. Blood 2003, 101:1430-1438.
52. Glauben R., Batra A., Fedke I., et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. JImmunol 2006, 176:5015-5022.
53. Glauben R., Batra A., Stroh T., et al. Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut 2008, 57:613-622.
54. Tao R., de Zoeten E.F., Ozkaynak E., et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007, 13:1299-1307.
55. Leng C., Gries M., Ziegler J., et al. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp Hematol 2006, 34:776-787.
56. Shlomchik W.D. Graft-versus-host disease. Nat Rev Immunol 2007, 7:340-352.
57. Banchereau J., Briere F., Caux C., et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811.
58. Sun Y., Chin Y.E., Weisiger E., et al. Cutting edge: negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J Immunol 2009, 182:5899-5903.
59. Levine J.E., Uberti J.P., Ayash L., et al. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy. Biol Blood Marrow Transplant 2003, 9:189-197.